Relieva is an anti-inflammatory cream with clinically proven effectiveness in psoriasis, atopic dermatitis, and problem skin
Reliéva™ Contains Psorberine™, the proprietary, highly concentrated extract of Mahonia aquifolium 10%. (Concentrated 75x for Enhanced Efficacy) Formulated using a patented Novasome® delivery system that enhances penetration and bioavailability of the active ingredient.
Reliéva™is registered as homeopathic product in the USA and natural compound in Canada
Mahonia aquifolium is listed in the European " Homeopathic Pharmacopeia" rendering rapid registration in Europe possible.
Available for a perpetual license with Performance ObjectivesUp front non-refundable License FeeRoyalty on Net SalesMinimum Performance ObjectivesOwner will manufacture the extract, partner can negotiate to buy, extract, bulk or finished goods Relieva trademark is available or can be partners own brand Regulatory Approval process is the Licensee's responsibility
Prime Pharmaceutical Corporation (Prime)invented a patented extraction process increasing the concentration of the beneficial alkaloids from Mahonia Aquifolium an ancient Indian Herbal remedy 75 times creating its proprietary extract “Psorberine”. Reliéva™ is an anti-inflammatory, antibacterial crème for the treatment of psoriasis and atopic dermatitis. It provides immediate relief for itching, irritation ands inflammation associated with almost all problem skin conditions with ZERO TOXICITY AND IRRITATION
The active component Psorberine™ consists of enriched alkaloids, extracted from the root of the plant Mahonia Aquifolium. The efficacy of the Reliéva™ crème was successfully tested in clinical studies on more than 500 patients with psoriasis or atopic dermatitis. With an efficacy that is at least comparable to standard therapies, Relieva™ displays a clearly superior side effect profile and apparently does not lose its effects after repeated applications.
Because of the low side effects and theimprovement of the quality of life described by patients, Reliéva™ qualifies as a superior basic therapy. In addition to the crème the Reliéva™ product line comprises a lotion and a shampoo. Prime has just created a new foam with 10x the concentration of alkaloids and beneficial molecules. Recent tests have shown this new foam comparable to the strongest steroids but without irritation, toxicity and side effects. In fact it is soothing.
Over $4,000,000 spent on published clinical trials, university and laboratory studies.
Psorberine is clinically proven to heal symptoms of most widespread skin conditions including psoriasis eczema;
Ø preventing cell proliferation, scaling and flaking resulting in smoothing skin
Ø relieving itching,
Ø relieving inflammation and pain associated with these symptoms
Meets all North American Regulatory requirements !
Health Canada recognized claims for the following items
Ø NPN 80002614 skin lotion
Ø NPN 80008473 skin cream
Ø FDA approved as a Homeopathic
World Wide Recognition for Safety and Efficacy !
Ø British Herbal Pharmacopeias
Ø American Homeopathic Pharmacopoea
Ø European Herbal Pharmacopea
Ø Relieva approved in AUSTRALIA
Distinct Competitive Advantages over Leading Pharmaceuticals
with sales of a $1.4 billion
Ø Does not lose efficacy overtime
Ø Diseases and skin conditions do not build up tolerability to treatment
Ø Zero irritancy proven milder than Dove soap in irritancy studies
Ø Unparallel combination of Safety and Efficacy
Patents and Trademarks
Patent and/or Trademark Applications filed in approximately 21 with full approval in ECC, U.S., Australia, China and several others Prime owns the world wide rights to Relieva we are in negotiations with several countries
Ø Clinical Proof - Published Clinicals
Reliéva® proven effective and safe in a 200 patient, Double Blind Placebo Controlled Study recently published in the American Journal of Therapeutics (13,121-126, 2006).
Clinical trial proves Relieva® very effective and safe for eczema and atopic dermatitis published in American Journal of Theraputics (14,442-446, 2007)
Eczema market is three times greater than psoriasis estimated at $21 billion annually.